Pages that link to "Q35250940"
Jump to navigation
Jump to search
The following pages link to Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. (Q35250940):
Displaying 50 items.
- BH3 domains other than Bim and Bid can directly activate Bax/Bak (Q24305138) (← links)
- Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer (Q24307748) (← links)
- BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents (Q24337209) (← links)
- Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia (Q24633394) (← links)
- Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy (Q24635408) (← links)
- Small-molecule Bcl-2 antagonists as targeted therapy in oncology (Q24646161) (← links)
- BH3 mimetics to improve cancer therapy; mechanisms and examples (Q24655483) (← links)
- Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents (Q26764833) (← links)
- Regulation of Bim in Health and Disease (Q26781203) (← links)
- Bcl-2 antagonists: a proof of concept for CLL therapy (Q26823996) (← links)
- BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions (Q26828031) (← links)
- The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy (Q26865760) (← links)
- Targeting the Bcl-2 family for cancer therapy (Q26866936) (← links)
- The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics (Q27010154) (← links)
- How cell death shapes cancer (Q27021441) (← links)
- Bcl-x(L) blocks a mitochondrial inner membrane channel and prevents Ca2+ overload-mediated cell death (Q27338716) (← links)
- Mitochondrial apoptosis and BH3 mimetics (Q28069552) (← links)
- Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy? (Q28085240) (← links)
- The cancer cell's "power plants" as promising therapeutic targets: an overview (Q28296259) (← links)
- The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity (Q28487756) (← links)
- Postnatal developmental regulation of Bcl-2 family proteins in brain mitochondria (Q28572255) (← links)
- Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci (Q29248527) (← links)
- HA14-1, but not the BH3 mimetic ABT-737, causes Ca2+ dysregulation in platelets and human cell lines. (Q30454476) (← links)
- A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival (Q31100573) (← links)
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity (Q33392920) (← links)
- Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease (Q33398808) (← links)
- ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia (Q33405436) (← links)
- Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. (Q33412553) (← links)
- Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma (Q33627051) (← links)
- Emerging Bcl-2 inhibitors for the treatment of cancer (Q33682689) (← links)
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia (Q33702409) (← links)
- Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer (Q33745649) (← links)
- Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells (Q33750838) (← links)
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. (Q33806087) (← links)
- Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. (Q33840360) (← links)
- Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells (Q34039998) (← links)
- Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. (Q34059078) (← links)
- Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199 (Q34135298) (← links)
- BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells (Q34168023) (← links)
- The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules (Q34195072) (← links)
- Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia (Q34231324) (← links)
- B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins (Q34249024) (← links)
- Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma (Q34323880) (← links)
- Rapid detection of an ABT-737-sensitive primed for death state in cells using microplate-based respirometry (Q34374169) (← links)
- Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia (Q34392488) (← links)
- A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis (Q34398390) (← links)
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia (Q34504188) (← links)
- ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells (Q34533975) (← links)
- Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia (Q34568840) (← links)
- An antiapoptotic role for telomerase RNA in human immune cells independent of telomere integrity or telomerase enzymatic activity (Q34683952) (← links)